CyCa OncoSolutions strives to develop molecular devices for programmable delivery of anticancer drugs directly into the cells.
Ours is a novel drug delivery device that crosses the membrane bilayer and delivers functional molecules into the cytoplasm or other cellular organelles as you instruct and fabricate it. We are exploring the potential of this device to deliver functional molecules such as
i) anticancer drugs and
ii) other water soluble dyes and
iii) imaging agents directly into the living cell.
Additionally, our technology is valuable for pharma and biotech companies to increase the brand lifecycle of their drugs/molecules.
Cancer is the one of the leading cause in mortality and morbidity worldwide (8.2 million death, 14 million new cases and expected rise by 70 % in next two decades) especially in the low- and middle-income countries. Successful development of CyCa delivery device has a potential of especially reducing the side effect of known chemotherapeutic drugs by efficient and specific intracellular delivery. This will have high societal and market impact. So our mission is to improve the quality of life of the cancer patients, advance the global fight against cancer and reduce the public health burden.
We strive to make an impact in oncology and be a one stop solution for cancer therapy and care in future.
Dr Nusrat J M Sanghamitra
Founder, CEO Ph D in Chemistry with ten years of research experience
Dr F. Shaik
CSO Ph.D in Structural Biology with 3 years of research experience
Dr Fazlul Haque Krishan
COO Physician with experience in health management
Ms Taiyyaba Kausar
Prof. A. G. Samuelson
Department of Inorganic and Physical Chemistry Indian Institute of Science ,Bangalore-India http://ipc.iisc.ac.in/~ashoka/
Prof. S. Mazumdar
Department of Chemical Science, Tata Institute of Fundamental Research, Mumbai-India http://www.tifr.res.in/~shyamal/
Dr M. Suar
Director, KIIT School of Biotechnology CEO, KIIT TBI
Pharma companies with special emphasis on R&D and oncology drug discovery programme
Live cell imaging market (biotech companies) (B2B)
Researchers in universities and research Institutes doing cell biology, nanobiotechnology (B2C)
Strategic partnership for co-development of product
Licensing patents (exclusive and non exclusive rights)
Possibility of early revenue by using the same technology to enter into the live-cell imaging market (it has low barrier due to absence of longer regulatory hurdles unlike that of pharma products)
Recombinantly designed protein with high stability and one step purification protocol, so easily scalable
Technology can be used in multiple market
Geographical advantage to avail low cost, high skilled HR